Table 2 Virologic outcomes
Parameter | Total | KTX-HD | KTX | |
|---|---|---|---|---|
DAA-KTX | KTX-DAA | |||
On-treatment response [n (%)] | 26 (100.0) | 11 (100.0) | 7 (100.0) | 8 (100.0) |
Time to first TnD, weeks [mean ± SD] | 1.9 ± 0.6 | 2.2 ± 0.6 | 1.7 ± 0.5 | 1.6 ± 0.5 |
Virologic relapse [n (%)] | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
SVR 48 [n (%)] | 26 (100.0) | 11 (100.0) | 7 (100.0) | 8 (100.0) |
Follow-up over 96 weeks after treatment cessation [n (%)] | 24 (92.3) | 9 (81.8) | 7 (100.0) | 8 (100.0) |
SVR 96 [n (%)] | 24 (100.0) | 9 (100.0) | 7 (100.0) | 8 (100.0) |